StockData

Neurogene vs Rocket Pharmaceuticals

NGNE and RCKT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NGNE and RCKT compare

Neurogene is the larger company, worth 2.0 times as much as Rocket Pharmaceuticals ($462M against $232M).

Neurogene scores higher on the StockData Score (7 against 3 for Rocket Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNGNERCKT
Size and price
Market cap$462M$232M
Share price$23.10$2.11
Change, 1 year1.4%−30.8%
Change, 5 years−77.4%−91.1%
Beta (5Y)2.012.32
Employees131202
StockData Score
Total score7 (better)3
Valuation score11
Growth score00
Performance score11
Health score5 (better)1
Dividend score00
Valuation
P/B2.1×0.6× (better)
FCF yield−19.0% (better)−73.6%
Profitability
Return on equity−45.3%−4.8% (better)
Return on invested capital–−180%
Financial health
Debt / equity0.00–
Interest coverage−60673.0×−101.3× (better)
Current ratio10.64 (better)9.24
Altman Z-score7.17 (better)−2.72
Piotroski F-score2 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions86.5%90.9%
Held by insiders15.9%22.3%
Insider net buying, 12 months−$1.1M−$934K (better)
Short interest, % of float33.8%19.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.